ALK B ALK-ABELLO A/S

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner:



Bestyrelsen har tidligere tildelt aktieoptioner og performance-aktier i ALK-Abelló A/S, jf. selskabs­meddelelse nr. 07/2022 af 24. marts 2022. Retten til aktieoptioner og performance-aktier kunne opnås i marts 2025, under forudsætning af, at ALK opnår de forud aftalte målsætninger for optjening, samt at ansættelses­forholdet i ALK-koncernen ikke er sagligt opsagt fra selskabets side eller op­hævet.



De endelige beregninger er nu foretaget, og den endelige tildeling af aktieoptioner og levering af performance-aktier har fundet sted som anført i den vedhæftede pdf-fil.



ALK-Abelló A/S

For yderligere oplysninger kontakt venligst:

Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525

Presse: Maiken Riise Andersen, tlf. 5054 1434

Vedhæftet fil



EN
04/03/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use i...

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland by making it eligible for general reimbursement. The recommendation of ITULAZAX® is another significant milestone for ALK, marking the sec...

July 21, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos...

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos voksne og børn i Storbritannien Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at det britiske Medicines and Healthcare Products Regulatory Agency (MHRA) har godkendt EURneffy® 2 mg til behandling af anafylaksi hos voksne og børn (≥30 kg) i Storbritannien. Lanceringen i Storbritannien ventes at ske inden for de kommende måneder, så snart forhandlinger om tilskud og prisfastsættelse er afsluttet. EURneffy® (varemærket for neffy® i EU og Storbritannien) er den første godkendte adrenalinnæsespray til akut...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® approved as the first needle-free anaphylaxis treatment of a...

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of adults and children (≥30 kg). The market launch in the UK is expected within the coming months once market access negotiations are completed. EURneffy® (the trade name for neffy® in the EU and the UK) constitutes the first approved adrenaline nasal spray for timely emergency treatm...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

First market launch of the adrenaline nasal spray, EURneffy®, for trea...

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions. With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, su...

June 26, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK presented comprehensive data on two new paediatric AIT tablets and...

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advanc...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch